Neutralising human recombinant antibodies to human cytomegalovirus glycoproteins gB and gH

FEMS Immunology and Medical Microbiology

Volumn 34, Issue 3, 2002, Pages 237-244

  Nejatollahi, Foroogh ^a   Hodgetts, Samantha J ^a   Vallely, Pamela J ^a   Burnie, James P ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cytomegalovirus; Neutralizing antibody; Single chain fragment variable; Therapy

Indexed keywords

EPITOPE; ISOPROTEIN; NEUTRALIZING ANTIBODY; RECOMBINANT ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; THROMBOSPONDIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIBODY ISOLATION; ANTIBODY SPECIFICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DNA FINGERPRINTING; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN INDUCTION; SEQUENCE ANALYSIS; VIRUS CULTURE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CELLS, CULTURED; CLONING, MOLECULAR; CYTOMEGALOVIRUS INFECTIONS; CYTOPATHOGENIC EFFECT, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; NEUTRALIZATION TESTS; PEPTIDE LIBRARY; PEPTIDES; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY; VIRAL ENVELOPE PROTEINS;

EID: 0037111918     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-8244(02)00400-5     Document Type: Article

References (52)

1. Pepose J.S., Holland G.N., Nestor M.S., Cochran A.J., Foos R.Y. Acquired immune deficiency syndrome: pathogenic mechanisms of ocular disease. Ophthalmology. 92:1985;472-484.
2. Grundy J.E. Virologic and pathogenetic aspects of cytomegalovirus infection. Rev. Infect. Dis. 12:(Suppl 7):1990;S711-S719.
3. Pepose J.S., Newman C., Bach M.C., Quinn T.C., Ambinder R.F., Holland G.N., Hodstrom P.S., Frey H.M., Foos R.Y. Pathologic features of cytomegalovirus retinopathy after treatment with the antiviral agent ganciclovir. Ophthalmology. 94:1987;414-424.
4. Chalasani N., Wilcox C.M. Gastrointestinal hemorrhage in patients with AIDS. AIDS Patient Care STDs. 13:1999;343-346.
5. Wolf D.G., Spector S.A. Diagnosis of human cytomegalovirus central nervous system disease in AIDS patients by DNA amplification from cerebrospinal fluid. J. Infect. Dis. 166:1992;1412-1415.
6. Reed E.C., Bowden R.A., Dandliker P.S., Lilleby K.E., Meyers J.D. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann. Intern. Med. 109:1988;783-788.
7. Patel R., Snydman D.R., Rubin R.H., Ho M., Pescovitz M., Martin M., Paya C.V. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation. 61:1996;1279-1289.
8. Metselaar H.J., Rothbarth P.H., Brouwer R.M., Wenting G.J., Jeekel J., Weimar W. Prevention of cytomegalovirus-related death by passive immunization: a double-blind placebo-controlled study in kidney transplant recipients treated for rejection. Transplantation. 48:1989;264-266.
9. Steinmuller D.R., Novick A.C., Streem S.B., Graneto D., Swift C. Intravenous immunoglobulin infusions for the prophylaxis of secondary cytomegalovirus infection. Transplantation. 49:1990;68-70.
10. Snydman D.R., Werner B.G., Dougherty N.N., Griffith J., Rubin R.H., Dienstag J.L., Rohrer R.H., Freeman R., Jenkins R., Lewis W.D., et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation: a randomized, double-blind, placebo-controlled trial - The Boston Center for Liver Transplantation CMVIG study group. Ann. Intern. Med. 119:1993;984-991.
11. Macdonald A.S., Belitzky P., Cohen A., Lee S. Cytomegalovirus disease prophylaxis in seronegative recipients of kidneys from seropositive donors by combination of cytomegalovirus-hyperimmune globulin and low-dose acyclovir. Transplant. Proc. 23:1991;1355-1356.
12. Nicol D.L., MacDonald A.S., Belitsky P., Lee S., Cohen A.D., Bitter-Suermann H., Lowen J., Whalen A. Reduction by combination prophylactic therapy with CMV hyperimmune globulin and acyclovir of the risk of primary CMV disease in renal transplant recipients. Transplantation. 55:1993;841-846.
13. Matthews R.C., Hodgetts S., Burnie J.P. Preliminary assessment of a human recombinant antibody fragment to hsp90 in murine invasive candidiasis. J. Infect. Dis. 171:1995;1668-1671.
14. Hoogenboom H.R., Henderikx P., de Haard H. Creating and engineering human antibodies for immunotherapy. Adv. Drug Deliv. Rev. 31:1998;5-31.
15. Burnie J.P., Matthews R.C., Carter T., Beaulieu E., Donohoe M., Chapman C., Williamson P., Hodgetts S.J. Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infect. Immun. 68:2000;3200-3209.
16. Simpson J.A., Chow J.C., Baker J., Avdalovic N., Yuan S., Au D., Co M.S., Vasquez M., Britt W.J., Coelingh K.L. Neutralizing monoclonal antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites. J. Virol. 67:1993;489-496.
17. Li L., Coelingh K.L., Britt W.J. Human cytomegalovirus neutralizing antibody-resistant phenotype is associated with reduced expression of glycoprotein H. J. Virol. 69:1995;6047-6053.
18. Boppana S.B., Britt W.J. Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J. Infect. Dis. 171:1995;1115-1121.
19. Beninga J., Kalbacher H., Mach M. Analysis of T helper cell response to glycoprotein H (gpUL75) of human cytomegalovirus: evidence for strain-specific T cell determinants. J. Infect. Dis. 173:1996;1051-1061.
20. Urban M., Klein M., Britt W.J., Hassfurther E., Mach M. Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J. Gen. Virol. 77:1996;1537-1547.
21. Reschke M., Revello M.G., Percivalle E., Radsak K., Landini M.P. Constitutive expression of human cytomegalovirus (HCMV) glycoprotein gpUL75 (gH) in astrocytoma cells: a study of the specific humoral immune response. Viral Immunol. 12:1999;249-262.
22. Rasmussen L., Matkin C., Spaete R., Pachl C., Merigan T.C. Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. J. Infect. Dis. 164:1991;835-842.
23. Plotkin S.A. Vaccination against cytomegalovirus, the changeling demon. Pediatr. Infect. Dis. J. 18:1999;313-325.
24. Navarro D., Paz P., Tugizov S., Topp K., La Vail J., Pereira L. Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells. Virology. 197:1993;143-158.
25. Kniess N., Mach M., Fay J., Britt W.J. Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus. J. Virol. 65:1991;138-146.
26. Silvestri M., Sundqvist V.A., Ruden U., Wahren B. Characterization of a major antigenic region on gp55 of human cytomegalovirus. J. Gen. Virol. 72:1991;3017-3023.
27. Meyer H., Sundqvist V.A., Pereira L., Mach M. Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. J. Gen. Virol. 73:1992;2375-2383.
28. Keay S., Baldwin B. Anti-idiotype antibodies that mimic gp86 of human cytomegalovirus inhibit viral fusion but not attachment. J. Virol. 65:1991;5124-5128.
29. Fuller A.O., Santos R.E., Spear P.G. Neutralizing antibodies specific for glycoprotein H of herpes simplex virus permit viral attachment to cells but prevent penetration. J. Virol. 63:1989;3435-3443.
30. Rasmussen L.E., Nelson R.M., Kelsall D.C., Merigan T.C. Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus. Proc. Natl. Acad. Sci. USA. 81:1984;876-880.
31. Urban M., Britt W., Mach M. The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific. J. Virol. 66:1992;1303-1311.
32. Burnie J.P., Brooks W., Donohoe M., Hodgetts S., al-Ghamdi A., Matthews R.C. Defining antibody targets in Streptococcus oralis infection. Infect. Immun. 64:1996;1600-1608.
33. Marks J.D., Hoogenboom H.R., Bonnert T.P., McCafferty J., Griffiths A.D., Winter G. By-passing immunization: human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222:1991;581-597.
34. Matthew R.C., Burnie J.P., Howat D., Rowland J. Autoimmunity to hsp90 can mediate protection against systemic candidiasis. Immunology. 74:1991;20-24.
35. Matthews R.C., Hodgetts S., Burnie J.P. Patient-derived phage antibody display library as a source of human recombinant antibodies to candidal hsp 90. Immunother. Infect. Disease. 6:1994;213-217.
36. Schofield D.J., Glamann J., Emerson S.U., Purcell R.H. Identification by phage display and characterization of two neutralizing chimpanzee monoclonal antibodies to the hepatitis E virus capsid protein. J. Virol. 74:2000;5548-5555.
37. Sanna P.P., Williamson R.A., De Logu A., Bloom F.E., Burton D.R. Directed selection of recombinant human monoclonal antibodies to herpes simplex virus glycoproteins from phage display libraries. Proc. Natl. Acad. Sci. USA. 92:1995;6439-6443.
38. Parren P.W., Ditzel H.J., Gulizia R.J., Binley J.M., Barbas C.F. III, Burton D.R., Mosier D.E. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS. 9:1995;F1-F6.
39. Boots L.J., McKenna P.M., Arnold B.A., Keller P.M., Gorny M.K., Zolla-Pazner S., Robinson J.E., Conley A.J. Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries. AIDS Res. Hum. Retroviruses. 13:1997;1549-1559.
40. Bjorling E., von Garrelts E., Morner A., Ehnlund M., Persson M.A. Human neutralizing human immunodeficiency virus type 2-specific Fab molecules generated by phage display. J. Gen. Virol. 80:1999;1987-1993.
41. Williamson R.A., Burioni R., Sanna P.P., Partridge L.J., Barbas C.F. III, Burton D.R. Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries. Proc. Natl. Acad. Sci. USA. 90:1993;4141-4145.
42. Sweet C. The pathogenicity of cytomegalovirus. FEMS Microbiol. Rev. 23:1999;457-482.
43. Compton T. Towards a definition of the HCMV entry pathway. Scand. J. Infect. Dis. Suppl. 199:1995;30-32.
44. Watkins B.A., Davis A.E., Fiorentini S., di Marzo Veronese F., Reitz M.S. Jr. Evidence for distinct contributions of heavy and light chains to restriction of antibody recognition of the HIV-1 principal neutralization determinant. J. Immunol. 156:1996;1676-1683.
45. Binley J.M., Ditzel H.J., Barbas C.F. III, Sullivan N., Sodroski J., Parren P.W., Burton D.R. Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen binding. AIDS Res. Hum. Retroviruses. 12:1996;911-924.
46. Ferrer M., Harrison S.C. Peptide ligands to human immunodeficiency virus type 1 gp120 identified from phage display libraries. J. Virol. 73:1999;5795-5802.
47. Kabat E.A., Wu T.T. Identical V region amino acid sequences and segments of sequences in antibodies of different specificities: relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. J. Immunol. 147:1991;1709-1719.
48. Fleury D., Daniels R.S., Skehel J.J., Knossow M., Bizebard T. Structural evidence for recognition of a single epitope by two distinct antibodies. Proteins. 40:2000;572-578.
49. Metselaar H.J., Balk A.H., Mochtar B., Rothbarth P.H., Weimar W. Cytomegalovirus seronegative heart transplant recipients: prophylactic use of anti-CMV immunoglobulin. Chest. 97:1990;396-399.
50. Steinmuller D.R., Graneto D., Swift C., Novick A.C., Streem S.B., Cunningham R.J., Hodge E., Bretan P. Use of intravenous immunoglobulin prophylaxis for primary cytomegalovirus infection post living-related-donor renal transplantation. Transplant. Proc. 21:1989;2069-2071.
51. Saliba F., Arulnaden J.L., Gugenheim J., Serves C., Samuel D., Bismuth A., Mathieu D., Bismuth H. CMV hyperimmune globulin prophylaxis after liver transplantation: a prospective randomized controlled study. Transplant. Proc. 21:1989;2260-2262.
52. Roy, D.M. and Grundy, J.E. (1992) Evaluation of neutralizing antibody titers against human cytomegalovirus in intravenous gamma globulin preparations. Transplantation 54, 1109-1110. Comment in: Transplantation (1993) 56, 765-766.